Chola Financial Holdings Q1 FY27: consol PAT +42% YoY to ₹1,789 Cr, beats street
PAT +42.03% YoY · revenue +19.55% · margins expanding · beat vs street
₹11,113.57 Cr
+19.55% YoY
₹1,788.99 Cr
+42.03% YoY
15.95%
+2.5pp YoY
₹42.92
Cholamandalam Financial Holdings' consolidated PAT came in at ₹1,789 Cr for Q1 FY27, up 42% YoY (₹1,259.54 Cr) and 10.1% QoQ (₹1,625.55 Cr), on consolidated total income of ₹11,214 Cr (+19.6% YoY, +6.4% QoQ). That beats the street: Univest's pre-result Q1 FY27 preview had pegged consolidated PAT in a ₹1,323-1,683 Cr range, and the actual print landed above the top end; CIFCL's own standalone PAT of ₹1,654 Cr similarly beat a separately reported analyst estimate of ₹1,560 Cr. The standalone entity itself is a pure investment-holding shell — total income of just ₹4.36 Cr and PAT of ₹4.38 Cr — so the consolidated numbers are what matter, and the holding company's own reported PAT actually exceeds the group figure only because of how minority interest is carved out below the line: owners' share of consolidated PAT is ₹805.96 Cr against ₹983.03 Cr of non-controlling interest, since CFHL holds only ~43.7% economic stake in CIFCL despite fully consolidating it.
Q1 FY-2027 vs prior quarters
The growth was broad-based across both operating arms. The financing segment (CIFCL) delivered PBT of ₹2,222 Cr, up 45.1% YoY, on disbursements of ₹29,612 Cr (+22% YoY) and AUM of ₹2,54,392 Cr (+23% YoY) — CIFCL's own release frames this as meeting the upper end of its FY27 AUM guidance band. Finance costs rose a slower 15.6% YoY (₹4,007 Cr vs ₹3,468 Cr), supporting margin. The bigger swing was in insurance: CMSGICL's segment PBT rebounded to ₹172.6 Cr from a ₹4.85 Cr loss in Q4 FY26, and improved modestly on ₹160.66 Cr a year ago, even as gross written premium grew only 6% YoY to ₹2,189 Cr — underwriting profitability, not topline, drove the recovery. Consolidated NPM expanded to 15.95% from 15.34% QoQ and 13.42% YoY, consistent with this operating leverage.
The stock went into the print at ₹1,594.9, up 2% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
CMSGICL GWP ₹2,189 Cr (+6% YoY), profit ₹128 Cr vs ₹119 Cr YoY, investment book ₹19,172 Cr
Consolidated basic EPS ₹42.92 vs ₹30.81 YoY / ₹36.59 QoQ
Management did not provide specific quantitative guidance but reiterated a medium-to-long-term target of 15%+ ROE. This recovery is predicated on improving the high motor OD loss ratio through recent 7-8% pricing corrections, with positive effects expected within six months. The company plans to restore top-line growth
— This quarter: beat
On guidance: management's May 2026 concall gave no formal quantitative target beyond a medium-to-long-term 15%+ ROE goal, but did flag that 7-8% motor OD pricing corrections at CMSGICL should show positive effect "within six months." The insurance segment's swing to profit shows up in the very next quarter — materially ahead of that stated timeline — so this reads as a beat against that specific guidepost, even though the standalone ROE target isn't independently verifiable from this statement. The other guided item, re-entry into crop insurance, has no corresponding disclosure in this quarter's segment data or the event record, so it remains unconfirmed. No exceptional corporate actions this quarter beyond routine board/AGM/BRSR items in the event log; none of those tie directly to the print.
W1
Whether CMSGICL's insurance PBT (₹172.6 Cr this quarter vs a ₹4.85 Cr loss last quarter) holds through Q2 FY27, confirming the motor OD loss-ratio recovery management flagged in the May 2026 concall
W2
Crop insurance re-entry flagged in prior concall guidance — no segment disclosure of it yet in Q1 FY27 results
W3
CIFCL AUM growth (+23% YoY to ₹2,54,392 Cr, at the top of its guided FY27 band) against finance costs growing at 15.6% YoY vs 22% disbursement growth
Chola's Momentum Play: AUM @ ₹2.54L Cr, Eyes on Asset Quality
The financial-services major faces a balancing act at earnings—growth in AUM and disbursements is on-track, but rising NPAs signal credit headwinds. Street expects 46% PAT growth and 22%+ income expansion, but the board's new CFO regime and margin pressure will dominate the read.
The Setup: Growth on Track, Credit Quality Under Pressure
Cholamandalam Investment & Finance enters Q1 FY27 earnings (result Aug 14) as a story of two halves. The positive: AUM has climbed 23% YoY to ~₹2.54 lakh crore, sitting at the upper end of management's 20–23% FY27 guidance. Disbursements are running at 22% growth, and total income is expected ~₹8,957 Cr (+22% YoY). Analysts widely expect a 46% YoY surge in PAT to ~₹1,656 Cr, a solid headline. The negative: gross non-performing assets have ticked up to 4.5%, from 4.29% a year ago, signaling credit stress in the portfolio. Management's medium-term ROE target of 16–18% remains unfulfilled—H1 H1 was only 6.2% (not annualized). The read will turn on whether this is Q1 noise or the start of a margin/credit-quality correction.
~₹1,656 Cr
46% YoY growth; street consensus
~22% YoY
to ~₹8,957 Cr; aided by AUM expansion
23% YoY
to ₹2.54L Cr; meets upper-end FY27 guidance (20–23%)
4.5%
up 21 bps from 4.29% YoY; Net NPA 2.95% (vs 2.86%)
What a Strong vs. Weak Print Looks Like
Strong print: PAT beats ₹1,656 Cr; GNPA dips below 4.5% or management signals NPA pressure is transitory (portfolio re-mix, not systemic). Margins hold firm or improve. AUM guidance ticked up to 23–25% for FY27. New CFO outlines cost/efficiency initiatives that build back to 16%+ ROE. Dividend policy reaffirmed at Aug 14 AGM. Weak print: PAT at or below ₹1,500 Cr (materially below 46% growth expectation). GNPA climbing further; Net NPA above 3%. Margins compress owing to higher provision requirements. AUM growth slowing to <20%. Management's medium-term ROE outlook pushed back or de-emphasized. Capital raise plans (₹55k Cr NCD program approved by board) trigger on liquidity concerns.
Street Consensus & Valuation
Since Last Quarter: Filings & Corporate Action
1 · CFO Transition (June 15, 2026)
N. Ganesh retired as CFO; Shyam Shankar appointed effective June 15. First results under new regime. Market will watch for clarity on cost discipline, credit controls, and capital allocation priorities.
2 · Capital Raise Approved (Board, Aug 14)
Board approved issuance of up to ₹55,000 Cr in non-convertible debentures (NCDs) across multiple tranches. Signals confidence in AUM expansion, but also highlights liquidity/funding optionality in a rising-rate environment.
3 · FY26 BRSR Report (July 22)
FY26 Business Responsibility & Sustainability Report released. Standard ESG disclosure; no material red flags flagged in headline.
4 · Ownership Drift
FII holdings down 4.5pp to 13.80%; DII up 2.55pp to 26.10%. Suggests marginal flight to domestic investors, possibly reflecting macro/sector concern among global investors on Indian NBFC credit quality.
5 · Dividend Record Date (Aug 7, 2026)
Record date for FY26 final dividend of ₹1.30/share (130% payout). Reflects confidence in cash generation despite softer H1 profitability (6.2% ROE).
What to Watch on Result Day
1 · Asset Quality Inflection
Is the 4.5% GNPA a one-off (seasonal, mix shift in portfolio) or the start of a structural deterioration? Management commentary on specific segments (vehicle, home, personal) and re-scoring trends critical.
2 · Margin Trajectory
Did provisions/NPA charges crimp spreads vs. a year ago? Q1 profit growth is expected at 46%, but if driven mainly by scale (AUM +23%) rather than margin expansion, it signals structurally softer returns ahead.
3 · FY27 AUM Guidance Reaffirmed?
Management guided 20–23% AUM growth for FY27. Q1 hit 23% (upper end). Will they hold, or tighten band given credit stress? A guide-down could rattle the stock.
4 · ROE Path Back to 16%
H1 ROE at 6.2% is well below medium-term target. New CFO's first results—does he outline a credible roadmap to recover profitability, or is it asset-quality troubleshooting?
Cholamandalam enters Q1 earnings as a momentum play on AUM and disbursement growth, but the print's credibility rests on asset quality. Street consensus expects 46% PAT growth and 22%+ income expansion, pricing in a recovery to 16–18% ROE. However, rising NPAs (4.5% GNPA) and persistent FII selling suggest investors remain skeptical of the credit cycle and execution under the new CFO regime. Watch for management's tone on NPA trajectory, provision adequacy, and the path to medium-term profitability. A beat on earnings but deteriorating asset signals could prove more bearish than a miss on the headline.